使用免疫标记进行的澳大利亚血液测试预测卵巢癌患者对PARP抑制剂的反应比DNA检测更准确。 An Australian blood test using immune markers predicts ovarian cancer patients' response to PARP inhibitors more accurately than DNA tests.

澳大利亚研究人员开发的一项新的血液测试可以更好地预测哪种卵巢癌病人通过测量肿瘤中与免疫细胞活动有关的免疫生物标志来对PARP抑制剂药物作出反应。 A new blood test developed by Australian researchers can better predict which ovarian cancer patients will respond to PARP inhibitor drugs by measuring immune biomarkers related to immune cell activity in tumors. 与目前的脱氧核糖核酸测试不同,这种非侵入性方法反映了实时癌症生物学,并显示准确性有所提高,特别是在以前被归类为不响应者的病人中。 Unlike current DNA-based tests, this non-invasive approach reflects real-time cancer biology and showed improved accuracy, especially in patients previously classified as non-responders. 这项测试在114名妇女临床试验中得到验证,有助于避免无效治疗,减少副作用,指导更个性化的护理。 The test, validated in a clinical trial of 114 women, could help avoid ineffective treatments, reduce side effects, and guide more personalized care. 虽然需要进一步验证,但专家们认为这是朝着卵巢癌精密医学迈出的有希望的一步。 While further validation is needed, experts view it as a promising step toward precision medicine in ovarian cancer.